Ikbkg Protein is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.
IκB Kinase Gamma (IKKγ or NEMO) is the regulatory subunit of the IκB kinase (IKK) complex. Encoded by the IKBKG gene, NEMO serves as a scaffold and regulatory component that is essential for IKK activation in response to pro-inflammatory stimuli. [1]
IKBKG Protein is a protein involved in critical biological pathways relevant to neurodegenerative diseases. It plays important roles in neuronal function, cellular signaling, mitochondrial maintenance, or stress response mechanisms that are essential for neuronal health. [2]
Dysregulation or mutations in this protein contribute to the pathogenesis of Alzheimer's disease, Parkinson's disease, and related neurodegenerative disorders through effects on protein function, inflammatory signaling, mitochondrial function, or cell survival pathways. [3]
--- [4]
NEMO is a 419 amino acid protein (approximately 48 kDa) that lacks intrinsic kinase activity but is essential for IKK complex function. The protein contains: [5]
NEMO forms a heterotrimeric complex with IKKα and IKKβ, functioning as: [6]
NEMO mediates IKK activation through multiple mechanisms: [7]
Key functions:
Activation pathways:
IKBKG is expressed in:
Brain distribution:
NEMO mutations and dysregulation are linked to:
Targeting NEMO/NF-κB:
Gene therapy potential:
IKBKG knockout mice:
Current research:
The study of Ikbkg Protein has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
2 Israel A. The NEMO protein: a key regulator of NF-κB activation. 2006. ↩︎
3 Karin M, Ben-Neriah Y. Phosphorylation meets ubiquitination: the control of NF-κB activity. 2000. ↩︎
4 Orange JS, Jain A, Ballas ZK, Schneider LC, Geha RS. The presentation and natural history of X-linked lymphoproliferative disease. 2004. ↩︎
5 Mattson MP, Meffert MK. Roles for NF-κB in nerve cell survival, plasticity, and disease. 2006. ↩︎
6 Camandola S, Mattson MP. NF-κB as a therapeutic target in neurodegenerative diseases. 2007. ↩︎
7 Zhu J, et al. NEMO in NF-κB activation. 2012. ↩︎
8 Smahi A, Courtois G, Rabia SH, et al. The NF-κB signalling pathway in human diseases: from germline mutations to multifactorial disorders. 2007. ↩︎